Canadian stem cell company restructures; MIT group, J&J unit collaborate on tumors;

Stem Cell Research

Undone by a high placebo effect in a mid-stage study, Canada's Stem Cell Therapeutics is cutting loose several top execs, including its CEO. Story

Extracted teeth appear to be an ideal source for pluripotent stem cells. Report

The California Institute for Regenerative Medicine has awarded four researchers from Stanford $5.6 million in new grant money. That was part of a $25 million package OK'd last week. Story

The stem cell research company Neuralstem has raised $10 million through the sale of shares and warrants. Story

Cancer Research

The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology has signed up with J&J's Ortho-McNeil-Janssen Pharmaceuticals on a 5-year pact to develop new R&D tumor technology. Story

Genetics

An international consortium including Helmholtz Zentrum München and the German Diabetes Center, Düsseldorf has identified 12 new gene variants which impact the individual's risk of developing type 2 diabetes. Release

A researcher from the Los Angeles Biomedical Research Institute led a team using cutting-edge technology to identify genes relevant to the study of Lou Gehrig's disease. Release

A high concentration of transposons, stretches of DNA sometimes referred to as "jumping genes," may play a big role in the development of lung tumors, further complicating an already complex field of genetics. Report

The NIH and the UK's Wellcome Trust are joining forces to conduct a $38 million study on the genetic and environmental triggers behind chronic diseases in Africa. Story

And Finally... The top 10 pharma cargo thefts of 2009/2010. Report

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.